May 18th 2024
A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Tapering, Withdrawal of Anti-TNFs Associated With Lower Costs, Worse Disease Control
August 29th 2017Treatment strategies involving anti-tumor necrosis factor dose tapering or withdrawal among rheumatoid arthritis patients who are achieving disease control are gaining popularity. Such strategies seek to optimize benefits versus risks with respect to both patient preferences and the high costs of biologic treatments.
Study: Patients and Providers Prefer Biosimilar Etanercept's Auto-Injector
August 29th 2017A recently published study found that the auto-injector device used to deliver a biosimilar etanercept was preferable to the auto-injector device used to deliver reference etanercept (Enbrel) among patients with rheumatoid arthritis and healthcare providers who treat patients with RA.
Biosimilar Endocrinology Roundup: August
August 28th 2017August saw notable developments in the market for insulins in the world of endocrinology biosimilars and follow-ons: new studies showed similarity between a challenger to branded insulin glargine; price competition gained momentum; and patients, providers, and state governments signaled an urgent need for diabetes drug prices to drop.
Prophylactic Treatment With G-CSF Can Prevent Chemotherapy-Induced Neutropenia
August 25th 2017Providing prophylactic treatment with granulocyte-colony stimulating factor to patients receiving chemotherapy may yield better chemotherapy-induced neutropenia, febrile neutropenia, and related hospitalization outcomes if patients receive prophylaxis at levels above guideline recommendations, according to a recent study.
Samsung Bioepis Gains EU Approval for Adalimumab Biosimilar
August 25th 2017Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, announced that it has received the European Commission’s (EC) approval for its adalimumab biosimilar (Imraldi), referenced on AbbVie’s blockbuster Humira.
Auto-Injector for Biosimilar Etanercept Equivalent in Dosing, Tolerability to Pre-Filled Syringe
August 23rd 2017A study published in the British Journal of Clinical Pharmacology demonstrated the bioequivalence of GP2015, a biosimilar etanercept treatment (Sandoz’s Erelzi), when delivered with an auto-injector and when delivered with pre-filled syringe in patients across a variety of body weights.
Real-World Evidence Shows Biosimilar Filgrastim Safe, Effective Against Febrile Neutropenia
August 21st 2017Febrile neutropenia (FN) is among the most common complications of chemotherapy, and a recent post-marketing, multi-center, real-world, non-interventional, epidemiological study sought to examine the use, safety, and efficacy of biosimilar filgrastim in the primary and secondary prevention of FN.
CVS Health Survey Finds Patients Ready for Cost-Saving Biosimilars
August 19th 2017Pharmacy Benefit Manager CVS Health, which has over 90 million members, has released the results of a survey it conducted of approximately 2000 people in the United States concerning patient perceptions of generic and biosimilar medications.